Bayer
This article was originally published in The Tan Sheet
Executive Summary
Agreement with Andrx covers use of the Fort Lauderdale, Fla.-based company's drug delivery technology for a controlled-release version of an undisclosed OTC product. The new deal follows another collaboration between the firms, announced in September 1997 ("The Tan Sheet" Sept. 29, 1997, In Brief). Andrx says the NDA for the first OTC product was recently submitted to FDA
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning